RxDoctor Payments Data

Mary Parker

Gerontology · Fort Wayne, INNPI 1386661064

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $10,768 of the $13,292 with a category attached, or 81.0%. Sun Pharmaceutical Industries Inc. accounts for 86.9% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2021 at $10,648 and has fallen 96.1% since, to $412 in 2025. Among gerontology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$13,292in general payments, 2019–2025

Across 53 payments — averaging $250.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$12K
  • Urovant Sciences Inc$867
  • Acadia Pharmaceuticals Inc$315
  • Bayer$107
  • Sanofi-aventis U.S. LLC$104
  • Otsuka America Pharmaceutical, Inc.$92
  • plus $261 from 7 others

What the payments were for

  • Speaking & faculty fees$10,76881%
  • Travel & lodging$8526%
  • Food & beverage$1,66713%
  • Education$50%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,292 in reported general payments places this provider in the 95th percentile of 230 gerontology providers in Indiana.

See all gerontology providers in Indiana

Medicare billing

Part B allowed, 2024
$48,443
Medicare patients
191
Services billed
763

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban81$39,047
JanuviaSitagliptin Phosphate29$16,662
XareltoRivaroxaban16$8,206
MyrbetriqMirabegron17$6,479
GemtesaVibegron26$6,300
Atorvastatin Calcium192$2,537
Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc22$2,360
Levothyroxine Sodium200$2,266
Metoprolol Succinate125$2,190
Memantine Hcl33$1,860
Duloxetine Hcl78$1,781
Mirtazapine62$1,780
Lidocaine19$1,668
Insulin Lispro Kwikpen U-100Insulin Lispro17$1,547
Midodrine Hcl31$1,383

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$57$6,30026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 230 gerontology providers in Indiana.

Other gerontology in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →